[en] [en] BACKGROUND: Recent data support 18F-FDG PET-CT for the management of infections in immunocompromised patients, including invasive fungal infection (IFI). However, its role is not well established in clinical practice. We performed an international survey to evaluate the knowledge of physicians about the usefulness of 18F-FDG PET-CT in IFI, in order to define areas of uncertainty.
METHODS: An online survey was distributed to infectious diseases working groups in December 2023-January 2024. It included questions regarding access to 18F-FDG PET-CT, knowledge on its usefulness for IFI and experience of the respondents. A descriptive analysis was performed.
RESULTS: 180 respondents answered; 60.5% were Infectious Diseases specialists mainly from Spain (52.8%) and Italy (23.3%). 84.4% had access to 18F-FDG PET-CT at their own center. 85.6% considered that 18F-FDG PET-CT could be better than conventional tests for IFI. In the context of IFI risk, 81.1% would consider performing 18F-FDG PET-CT to study fever without a source and around 50% to evaluate silent lesions and 50% to assess response, including distinguishing residual from active lesions. Based on the results of the follow-up 18F-FDG PET-CT, 56.7% would adjust antifungal therapy duration. 60% would consider a change in the diagnostic or therapeutic strategy in case of increased uptake or new lesions. Uncovering occult lesions (52%) and diagnosing/excluding endocarditis (52.7%) were the situations in which 18F-FDG PET-CT was considered to have the most added value. There was a great variability in responses about timing, duration of uptake, the threshold for discontinuing treatment or the influence of immune status.
CONCLUSION: Although the majority considered that 18F-FDG PET-CT may be useful for IFI, many areas of uncertainty remain. There is a need for protocolized research to improve IFI management.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Gutiérrez-Villanueva, A ; Infectious Diseases Unit, Internal Medicine Department, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
Calderón-Parra, J; Infectious Diseases Unit, Internal Medicine Department, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
Callejas-Diaz, A; Infectious Diseases Unit, Internal Medicine Department, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
Muñez-Rubio, E; Infectious Diseases Unit, Internal Medicine Department, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
Velásquez, K; Nuclear Medicine Department, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
Ramos-Martínez, A; Infectious Diseases Unit, Internal Medicine Department, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain ; Facultad de Medicina, Universidad Autónoma de Madrid (UCM), Madrid, Spain
Rodríguez-Alfonso, B; Nuclear Medicine Department, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
Fernández-Cruz, A; Infectious Diseases Unit, Internal Medicine Department, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. anafcruz999@gmail.com ; Facultad de Medicina, Universidad Autónoma de Madrid (UCM), Madrid, Spain. anafcruz999@gmail.com
Other collaborator :
LAYIOS, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > > Service des soins intensifs
Language :
English
Title :
What do we know About the Usefulness of 18F-FDG PET-CT for the Management of Invasive Fungal Infection? An International Survey.
Publication date :
16 September 2024
Journal title :
Mycopathologia
ISSN :
0301-486X
eISSN :
1573-0832
Publisher :
Springer Science and Business Media B.V., Netherlands
We thank all the survey respondents for taking their time to answer the questions. Special thanks to Ana Alastruey, Maddalena Giannella, Antonio Vena, Jon Salmanton, Maricela Valerio, Rafael Duarte, Eleni Magira and Miguel Salavert for their dedicated help to diffuse the survey. Adaia Albasanz Puig; Ahmed Kamal Bayoumi; Alba Bergas; Alberto D\u00EDaz de Santiago; Alberto Enrico Maraolo; Alberto Mart\u00EDnez Lorca; Alejandro Avenda\u00F1o Pita; Alessandra Bandera; Alessandra Mularoni; Alessandra Ricciardi; Alessandro Busca; Alessandro Russo; Almudena de La iglesia; \u00C1lvaro Irigoyen von Sierakowski; Amaia Mar\u00ED Hualde; Ana Alarc\u00F3n Tom\u00E1s; Ana \u00C1lvarez- Ur\u00EDa; Ana Bel\u00E9n Cuenca Abarca; Ana Cristina Hern\u00E1ndez Mart\u00EDnez; Ana Mu\u00F1oz; Andr\u00E9 Silva-Pinto; Andrea Prolo-Acosta; Angela Loizidou; Anna Carretta; Antonio Vena; Arias Milla; Athanasios Tragiannidis; Athina Pyrpasopoulou; Bart Rijnders; Beatriz Dietl; Bego\u00F1a Rodr\u00EDguez-Alfonso; Bel\u00E9n Loeches Yague; Beno\u00EEt Henry; Beyza Erol; Bismarck Bisono; Carlos Bea Serrano; Carlota Gudiol Gonz\u00E1lez; Caterina Campoli; Celia Cardozo; Chiara Oltolini; Chizaram Onyeaghala; Claudia Fabrizio; Cristina L\u00F3pez Rodr\u00EDguez; Dalla Gasperina Daniela; Deepak Kumar; Douwe Postma; Effrossyni Gkrania-Klotsas; Elena Bereciartua; Elena Garc\u00EDa Guijarro; Eleni Magira; Elisa Ruiz; Elisa Vanino; Elizabet Petkova Saiz; Eloy E. Ordaya; Emanuela Zappulo; Emanuele Palomba; Emmanuel Roilides; Emmanuel Roilides; Enric Sastre Escol\u00E0; Erica Franceschini; Esma Eryilmaz-Eren; Estela Moreno Garc\u00EDa; Etienne Daguindau; Fabio Rigo; Fanny Lanternier; Filippo Del Puente; Francesca Montagnani; Francisco Javier Candel Gonz\u00E1lez; Francisco L\u00F3pez-Medrano; Giacomo Stroffolini; Giulio Viceconte; Giuseppe Accurso; Guiomar Bautista Carrascosa; Gustavo A. M\u00E9ndez; Hee-Seung Henry Bom; Ignacio Morr\u00E1s; Igor Stoma; Isabel Gonz\u00E1lez; Isabel Guti\u00E9rrez Mart\u00EDn; Isabel Rodr\u00EDguez Goncer; Isabel Ruiz Camps; Isolina Ba\u00F1os P\u00E9rez; Jannik Helweg-Larsen; Jannik Stemler; Jes\u00FAs Fort\u00FAn; Jose Emilio Ballester Belda; Jose Ignacio Mateo Gonz\u00E1lez; Jose Mar\u00EDa Aguado Garc\u00EDa; Juan Carlos Ramos Ramos; Juan E. Losa-Garc\u00EDa; Juan Flores Cid; J\u00FAlia Laporte Amarg\u00F3s; Karel Santamaria Leandro; Karen Lausch; Karin van Dijk; Karina Vel\u00E1squez; Klaus Leth Mortensen; Laura Escol\u00E0-Verg\u00E9; Laura L\u00F3pez Gonz\u00E1lez; Leonardo Pagani; Liat Ashkenazi Hoffnung; Lourdes Vazquez Lopez; Luis Buz\u00F3n Martin; Lurdes Santos; M\u00AA Luisa Serrano Salazar; M\u00AA Teresa L\u00E1zaro; Maddalena Giannella; Malgorzata Mikulska; Manuela Aguilar Guisado; Manuela Carugati; Mar Alcalde Encinas; Marco Cilliano; Marco Libanore; Marco Merli; Marco Ripa; Marcos Hern\u00E1ndez Jim\u00E9nez; Maria Alejandra Mendoza; Mar\u00EDa Jos\u00E9 N\u00FA\u00F1ez; Mar\u00EDa Luz Dom\u00EDnguez Grande; Mar\u00EDa Paniagua; Maria Rosa Oltra sempere; Mar\u00EDa Stefania Infante; Mar\u00EDa Velasco Arribas; Maricela Valerio; Marina Machado; Mario Fern\u00E1ndez Ruiz; Mario Rosario Lo Storto; Marta Montero Alonso; Marta Sanz Garc\u00EDa Rosa; Matteo Rinaldi; Mi Kwon; Michele Trezzi; Miguel Salavert Lleti; Nathalie Layios; Nicolas Mueller; Nikola Pantic; Nina Khanna; Nischal Ranganath; Ola Blennow; Olga Kampouropoulou; Paloma Gij\u00F3n Vidaurreta; Patricia Monzo Gallo; Patricia Mu\u00F1oz; Patricia Paredes; Paula Villares; Pedro Gonz\u00E1lez Sierra; Pedro Puerta-Alcalde; Pierluigi Brugnaro; Pilar Martin Davila; Rafael Duarte F.; Raquel Monsalvo Arroyo; Regino Rodriguez-Alvarez; Renato Pascale; Robert Krause; Rosa Fern\u00E1ndez L\u00F3pez; Rosa Mar\u00EDa Mart\u00EDnez \u00C1lvarez; Rosal\u00EDa Laporta Hern\u00E1ndez; Rosanne Sprute; Rosario Cultrera; Salom\u00E9 Sanz Viedma; Sara de la Fuente; Sara Seijas Marcos; Sebasti\u00E1n Rizkallal Monz\u00F3n; Serena Trovati; Serino Francesco Saverio; Vicente Abril Lopez de Medrano; Vicente Boix; V\u00EDctor Moreno-Torres; Yasemin Tezer Tekce; Zach Yetmar; Zaira Palacios Baena.
A.O. Ankrah D. Creemers-Schild B. de Keizer H.C. Klein R. Dierckx T.C. Kwee et al. The added value of [(18)F]FDG PET/CT in the management of invasive fungal infections Diagnostics 2021 11 1 137 10.3390/diagnostics11010137 33477267 7830875
A.P. Douglas K.A. Thursky L.J. Worth E. Drummond A. Hogg R.J. Hicks et al. FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging Eur J Nucl Med Mol Imaging 2019 46 1 166 173 10.1007/s00259-018-4062-8 29882160
A. Gutierrez B. Rodriguez K. Velasquez I. Gutierrez S. Garcia E. Munez et al. Determining the usefulness of systematic (18)F-FDG PET/CT for the management of invasive fungal infection (PETIFI project): a prospective national multicentre cohort study protocol BMJ Open 2023 13 6 e074240 10.1136/bmjopen-2023-074240 37355275 10314664
A. Douglas K. Thursky M. Slavin New approaches to management of fever and neutropenia in high-risk patients Curr Opin Infect Dis 2022 35 6 500 516 10.1097/QCO.0000000000000872 35947070
A. Douglas K. Thursky T. Spelman J. Szer A. Bajel S. Harrison et al. [(18)F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial Lancet Haematol 2022 9 8 e573 e584 10.1016/S2352-3026(22)00166-1 35777413
C.P. Bleeker-Rovers F.J. Vos W.T. van der Graaf W.J. Oyen Nuclear medicine imaging of infection in cancer patients (with emphasis on FDG-PET) Oncologist 2011 16 7 980 991 10.1634/theoncologist.2010-0421 21680576 3228133
F.J. Vos C.P. Bleeker-Rovers W.J.G. Oyen The use of FDG-PET/CT in patients with febrile neutropenia Semin Nucl Med 2013 43 5 340 348 10.1053/j.semnuclmed.2013.04.007 23905616
A. Gafter-Gvili M. Paul H. Bernstine L. Vidal R. Ram P. Raanani et al. The role of 18F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia Leuk Res 2013 37 9 1057 1062 10.1016/j.leukres.2013.06.025 23849986
F.J. Vos J.P. Donnelly W.J.G. Oyen B.J. Kullberg C.P. Bleeker-Rovers N.M.A. Blijlevens 18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation Eur J Nucl Med Mol Imaging 2012 39 1 120 128 10.1007/s00259-011-1939-1 21947022
B. Leroy-Freschini G. Treglia X. Argemi C. Bund R. Kessler R. Herbrecht et al. 18F-FDG PET/CT for invasive fungal infection in immunocompromised patients QJM 2018 111 9 613 622 10.1093/qjmed/hcy128 29917146
A. Contejean A. Maillard E. Canoui S. Kerneis B. Fantin D. Bouscary et al. Advances in antibacterial treatment of adults with high-risk febrile neutropenia J Antimicrob Chemother 2023 78 9 2109 2120 10.1093/jac/dkad166 37259598
A. Gutierrez-Villanueva C. Quintana-Reyes E. Martinez de Antonio B. Rodriguez-Alfonso K. Velasquez A. de la Iglesia et al. Usefulness of (18)F-FDG PET-CT in the management of febrile neutropenia: a retrospective cohort from a Tertiary University Hospital and a systematic review Microorganisms. 2024 12 2 307 10.3390/microorganisms12020307 38399711 10893204
S. Hess FDG-PET/CT in fever of unknown origin, bacteremia, and febrile neutropenia PET Clin 2020 15 2 175 185 10.1016/j.cpet.2019.11.002 32145888
I.G.-P.S. Gutiérrez-Martín K. Velásquez et al. Usefulness of 18F-FDG PET-CT for the management of invasive fungal infections: a retrospective cohort from a tertiary university hospital Mycoses 2024 67 2 e13701 10.1111/myc.13701
V. Delgado N. Ajmone Marsan S. de Waha N. Bonaros M. Brida H. Burri et al. ESC Guidelines for the management of endocarditis Eur Heart J 2023 10.1093/eurheartj/ehad193 37622660 10691193
S.D. Guy A.R. Tramontana L.J. Worth E. Lau R.J. Hicks J.F. Seymour et al. Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients Eur J Nucl Med Mol Imaging 2012 39 8 1348 1355 10.1007/s00259-012-2143-7 22584486
K.C. Koh M.A. Slavin K.A. Thursky E. Lau R.J. Hicks E. Drummond et al. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia Leuk Lymphoma 2012 53 10 1889 1895 10.3109/10428194.2012.677533 22448920
G. Chamilos H.A. Macapinlac D.P. Kontoyiannis The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections Med Mycol 2008 46 1 23 29 10.1080/13693780701639546 18297544
A.P. Douglas K.A. Thursky L.J. Worth S.J. Harrison R.J. Hicks M.A. Slavin Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists Intern Med J 2019 49 5 615 621 10.1111/imj.14117 30230669
M. Tew A.P. Douglas J. Szer A. Bajel S.J. Harrison S.Y. Tio L.J. Worth R.J. Hicks D. Ritchie M.A. Slavin K.A. Thursky K. Dalziel Evaluating the cost-effectiveness of [18F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients Cancer Imaging 2023 23 1 119 10.1186/s40644-023-00647-7.PMID:38102639;PMCID:PMC10724891 38102639 10724891
A. Douglas E. Lau K. Thursky M. Slavin What, where and why: exploring fluorodeoxyglucose-PET’s ability to localise and differentiate infection from cancer Curr Opin Infect Dis 2017 30 6 552 564 10.1097/QCO.0000000000000405 28922285
J.Y. Kim J.W. Yoo M. Oh S.H. Park T.S. Shim Y.Y. Choi et al. (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography findings are different between invasive and noninvasive pulmonary aspergillosis J Comput Assist Tomogr 2013 37 4 596 601 10.1097/RCT.0b013e318289aa31 23863538
S.P. Salomaki A. Saraste P. Jalava-Karvinen L. Pirila U. Hohenthal Prosthetic valve candida endocarditis: a case report with 18F-FDG-PET/CT as part of the diagnostic workup Case Rep Cardiol 2020 2020 4921380 10.1155/2020/4921380 33294230 7714588
A. Fernandez-Cruz R.E. Lewis D.P. Kontoyiannis How long do we need to treat an invasive mold disease in hematology patients? Factors influencing duration of therapy and future questions Clin Infect Dis 2020 71 3 685 692 10.1093/cid/ciz1195 32170948 7384309
F. Lanternier D. Seidel L. Pagano J. Styczynski M. Mikulska C. Pulcini et al. Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: an EFISG, IDWP-EBMT EORTC-IDG and SEIFEM surv Mycoses 2020 63 5 420 429 10.1111/myc.13056
A.O. Ankrah M.M. Sathekge R. Dierckx A. Glaudemans Radionuclide imaging of fungal infections and correlation with the host defense response J Fungi 2021 7 6 407 10.3390/jof7060407
T.C. Kwee G. Cheng M.G. Lam S. Basu A. Alavi SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions Eur J Nucl Med Mol Imaging 2013 40 10 1475 7 10.1007/s00259-013-2484-x 23801170
R. Muzaffar E. Koester S. Frye S. Alenezi B.B. Sterkel M.M. Osman Development of simple methods to reduce the exposure of the public to radiation from patients who have undergone (18)F-FDG PET/CT J Nucl Med Technol 2020 48 1 63 67 10.2967/jnmt.119.233296 31604894
S. Leide-Svegborn Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG Radiat Prot Dosimetry 2010 139 1–3 208 213 10.1093/rpd/ncq026 20167792
